Although prolonged periods of neutropenia are common following induction and intensification of chemotherapy, this study showed that pediatric patients with AML can be safely managed in the outpatient setting after resolution of neutropenia.
Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.
A putative mechanism of resistance to BCMA-directed CAR-T therapy involves BCMA antigen loss through cleavage of BCMA from the surface of myeloma cells.
Little is currently known about how molecular alterations interact in the oncogenesis of follicular lymphoma.
For patients with early unfavorable Hodgkin lymphoma, disease control was improved with a dose-intensified regimen, but no overall survival gain was seen.
Addressing increased adverse events could be unmet medical need for Medicare-aged patients.
Combining vemurafenib with obinutuzumab in patients with relapsed or refractory HCL resulted in a complete response rate of 100% in the frontline setting.
Although allogeneic HSCT is considered the treatment of choice for patients with relapsed B-ALL, a number of potential barriers to its implementation can exist.
Eligibility criteria for this study included intermediate- or high-risk cytogenetics, and CR or CR with incomplete count recovery following induction chemotherapy.
The second-generation Bruton tyrosine kinase inhibitor tirabrutinib (ONO/GS-4059) showed promising efficacy in patients with treatment-naive (TN) or relapsed/refractory (RR) Waldenström macroglobulinemia (WM).
Many of the patients with WM included in this retrospective study had received multiple lines of treatment.
Inotuzumab ozogamicin (InO) exhibits clinical efficacy against heavily pretreated, relapsed CD22-positive pediatric B-cell acute lymphoblastic leukemia (B-ALL).
While PRO-CTCAEs capture patient reports of particular symptomatic AEs, the “toxicity over time” approach provides a longitudinal assessment of these AEs.
In this study, claims data from CMS were used to estimate health care utilization of patients with DLCBL before and after CAR-T therapy.
“Among evaluable patients who were transfusion dependent on ruxolitinib, 6 of 14 patients converted to transfusion independence after the addition of CPI-0610.”
Long-term follow-up from the clinical trial investigating LCAR-B38M, a BCMA-targeting CAR-T, revealed that approximately three-quarters of patients achieved a complete response.
JNJ-4528 is a CAR-T therapy in which 2 antibodies against the B-cell maturation antigen BCMA are expressed on T cells.
There was no benefit observed with the use of rituximab in the maintenance setting in Waldenström macroglobulinemia.
No detectable differences were found in major response rate at 6 months and 12 months between patients with and without CXCR4 mutations.
Researchers suggest expansion of double-hit testing to all DLBCL patients.